Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole with or without metronomic Capecitabine in ER+ HER2- advanced breast cancer
NCT04571437Phase 2Unknown
- Sponsor
- Cairo University
- Start
- Mar 2020
- Primary completion
- Oct 2021
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine in breast cancer, sponsored by Cairo University. Primary endpoint: 6 months Progression-Free Survival rate. Status: unknown.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04571437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04571437.